The Russian company FSUE Endopharm (Moscow Endocrine Plant) is launching the uroprotector Mesna on the Russian market for cancer patients. The intravenous solution is used to protect the bladder from the toxic effects of chemotherapeutic drugs.
By the end of January 2026, the enterprise will fully meet the Russian Federation’s demand for the drug Mesna, stated the Endopharm press service. The first batches of the uroprotector will be supplied to Moscow hospitals in the near future, including the Botkin and Morozov hospitals.
The drug is completely identical to the originator, which is not under patent protection in the territory of the Eurasian Economic Union, the statement said. Mesna is included in national clinical guidelines and is used as part of combination chemotherapy for ovarian cancer, breast cancer, lung cancer, head and neck cancers, bone and soft tissue sarcomas, lymphoma, and leukemia.
The original innovator drug with the INN Mesna, Uromitexan, is produced by the German company Baxter. Three other Russian companies—Atoll, Veropharm, and Lens-Farm—also manufacture its generics.